ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements
Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager (Head QA), a Senior Management Personnel. He departs effective 24 September 2026 for personal reasons.
Lincoln Pharmaceuticals has dispatched physical letters to shareholders with unregistered email IDs to provide access to the Annual Report for FY 2025-26 and facilitate KYC updates.
Lincoln Pharmaceuticals submitted its Annual Report for FY 2025-26 and notice for the 32nd Annual General Meeting scheduled for September 30, 2026.
Lincoln Pharmaceuticals declared a final dividend of ₹1.80 per equity share for FY 2025-26. The 32nd AGM is scheduled for September 30, 2026.
Lincoln Pharmaceuticals announced its 32nd AGM for September 30, 2026, and book closure dates from September 12 to 30, 2026, to determine dividend entitlement.
Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹177.3 Cr (+15.1% YoY) and net profit of ₹36.2 Cr (+30.7% YoY) for Q1 FY27.
Lincoln Pharmaceuticals Ltd will hold a board meeting on August 13, 2026. The board will consider and approve unaudited financial results for the quarter ended June 2026.
Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹187.3 Cr (+11.4% YoY) and net profit of ₹11.6 Cr (+0.0% YoY) for Q4 FY26.
Lincoln Pharmaceuticals reported a consolidated net profit of ₹87.89 Crore for FY26. The board recommended an 18% dividend, signaling consistent shareholder returns and stable growth.
Lincoln Pharmaceuticals scheduled a May 28 board meeting to approve annual financial results and dividend recommendations. This advance notice signals upcoming performance and payout disclosures.
Lincoln Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence with no major non-compliances.
Lincoln Pharmaceuticals Ltd confirmed it does not meet the SEBI criteria for 'Large Corporate' classification for FY 2025-26. The company reported zero outstanding long-term borrowings and zero mandatory debt sourcing requirements for the period, maintaining its status as a mid-sized corporate entity for regulatory purposes.
Lincoln Pharmaceuticals Ltd submitted its initial disclosure for FY 2026-27, confirming it does not fall under the Large Corporate category as of March 31, 2026. The company reported no outstanding borrowings under the framework's criteria. This routine regulatory filing follows SEBI's debt market borrowing requirements for listed entities.
Lincoln Pharmaceuticals Limited clarified to the NSE that its standalone and consolidated financial figures for Q2 FY2026 are identical because its sole subsidiary had no financial transactions during that period. This response addresses the exchange's query regarding financial result formatting and confirms the accuracy of the previously reported results.
Lincoln Pharmaceuticals Ltd submitted its quarterly confirmation certificate for the period ended March 31, 2026, as required under SEBI regulations. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed that security certificates received for dematerialisation were processed and listed on the stock exchanges within prescribed timelines.